Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Aug 03, 2026
Oracle (ORCL): Can It Reclaim $300 After a -48% Drop?

Oracle (ORCL): Can It Reclaim $300 After a -48% Drop?

Key Takeaways

  • Oracle trades near $130 after plunging over 48% in the past year from its all-time high of $345.72, putting the $300 target roughly 130% above current levels.
  • The strongest bullish argument is Oracle's staggering $638 billion remaining performance obligations (RPO) backlog, representing nearly 10 times annual revenue and signaling extraordinary future demand for its cloud infrastructure.
  • Oracle Cloud Infrastructure (OCI) revenue continues accelerating, growing 84% to 93% year-over-year in recent quarters, driven by AI training workloads from customers including OpenAI, Meta, and NVIDIA.
  • The biggest obstacle is Oracle's ballooning debt load of approximately $167 billion and deeply negative free cash flow, as the company spends tens of billions annually building AI data centers before that revenue materializes.
  • Wall Street analysts remain broadly constructive, with consensus price targets around $248 to $261 and select firms such as TD Cowen and KeyBanc maintaining $300 targets, though several firms have cut estimates in 2026.
  • Reaching $300 would likely require sustained OCI growth above 80%, successful conversion of the RPO backlog into recognized revenue, and margin recovery as data center capacity reaches contractual utilization levels — a timeline that probably extends into 2027 or 2028.

Why Investors Are Watching for a $300 Recovery

Oracle Corporation (ORCL) reached an all-time high of $345.72 in September 2025, fueled by optimism around its role as a key AI infrastructure provider. Since then, the stock has fallen more than half its value amid worries over heavy capital spending, rising debt, and negative free cash flow. With shares now near $130 — down approximately 48% over the past twelve months — the possibility of a return to $300 stands out as one of the more closely watched questions in tech investing. The stock traded above $300 as recently as mid-2025, so this level serves as both a psychological and technical reference point.

Oracle's Current Market Position

Oracle's fiscal 2026 revenue reached $67.4 billion, up 17% year-over-year, while net income rose 37% to approximately $17 billion. The company trades at a price-to-earnings (P/E) ratio of roughly 22, well below its own five-year median P/E of about 32 and the broader technology sector average near 34. This valuation reflects investor caution around Oracle's capital structure more than doubts about revenue growth. The company ended fiscal 2026 with $638 billion in RPO — a 363% increase from the prior year — which offers strong visibility into future revenue. Approximately $77 billion of that backlog is expected to convert into recognized revenue during fiscal 2027 alone. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Bullish Drivers for a $300 Move

The case for Oracle reaching $300 centers on its fast-growing cloud infrastructure business. OCI revenue surged 84% to 93% year-over-year in recent quarters, supported by strong demand for AI training compute. Oracle's role in Project Stargate — the $500 billion AI infrastructure initiative alongside SoftBank, NVDA, and OpenAI — places it at the center of one of the largest technology buildouts in history. Oracle has also signed major cloud contracts with META and other large customers. Management guided for fiscal 2027 revenue of approximately $90 billion, a 34% increase, and analysts project fiscal 2028 revenue could reach $130 billion as OCI capacity comes online. Combined with expectations that infrastructure margins will improve once data centers reach full utilization, Oracle's EPS could surpass $10 by fiscal 2028. At a 30x P/E multiple — in line with Oracle's three-year historical average — that would support a stock price above $300.

Risks That Could Derail the Recovery

The challenges are significant and explain much of the current valuation. Oracle's debt load rose from approximately $85 billion to roughly $167 billion over the past year to fund data center construction. Free cash flow turned deeply negative at negative $23.7 billion in fiscal 2026. S&P downgraded Oracle's credit rating to BBB-, and credit default swap spreads widened. The company plans to raise an additional $40 billion through debt and equity in fiscal 2027, including a $20 billion share sale that will dilute existing shareholders. Oracle also cut approximately 21,000 jobs — about 13% of its workforce — during fiscal 2026 as part of an AI-driven restructuring. Gross margins are expected to face near-term pressure as new data centers ramp up before reaching full utilization. If AI infrastructure demand slows or hyperscale customers reduce GPU prepayments, the RPO conversion story could weaken.

What Analysts Are Saying

Wall Street remains cautiously optimistic overall. Of approximately 44 analysts covering Oracle, the majority rate the stock a Buy or Strong Buy, with an average 12-month price target near $248 to $261 — implying roughly 90% to 100% upside from current levels. The range is wide: the most cautious targets sit around $155 to $160, while Guggenheim maintains a high target of $400. TD Cowen, KeyBanc, and several other firms hold at $300. However, multiple firms — including Baird, Piper Sandler, and BMO Capital — have lowered their targets during 2026 amid concerns about financing needs and the timeline for margin recovery.

Key Technical Levels to Watch

From a technical standpoint, Oracle trades well below all major moving averages, approximately 21% beneath its 50-day moving average and roughly 28% under its 200-day moving average. The 52-week low of $114.50 represents important support — a break below that level would indicate further weakness. On the upside, the $200 level marks the first significant resistance zone, aligning with several revised analyst targets. Beyond $200, the $250 zone — near consensus — forms the next hurdle, with $300 serving as both a psychological round number and the key recovery target. The stock's beta of 1.71 highlights its sensitivity to shifts in market sentiment around AI spending.

Final Assessment

The question of whether Oracle can reach $300 again is not about demand — the $638 billion RPO backlog confirms that clearly. The real issues are whether Oracle can finance its infrastructure buildout without damaging its balance sheet and convert booked contracts into recognized revenue and free cash flow before credit markets grow impatient. The path to $300 likely requires sustained OCI growth above 80% through at least fiscal 2027 and visible margin improvement as data centers reach full utilization. Neither is guaranteed, but both are supported by contract data and management guidance. Investors should monitor quarterly OCI revenue growth rates, RPO conversion trends, gross margin trajectory, and any changes to Oracle's financing plans. A return to $300 probably extends into late 2027 or 2028, depending on execution that bridges the gap between the company's demand pipeline and its capital requirements.

AI Daily Buy/Sell Signals

To navigate volatile situations like this one, I often turn to Tickeron’s AI Daily Buy/Sell Signals. The tool uses artificial intelligence to monitor thousands of stocks and generate Buy, Sell, or Hold signals based on technical patterns and market conditions, helping separate real trend shifts from short-term noise when following a multi-year recovery story like Oracle’s.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ORCL

ORCL sees its Stochastic Oscillator ascending out of oversold territory

On October 02, 2026, the Stochastic Oscillator for ORCL moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In 44 of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over 75%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +3.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORCL advanced for three days, in 227 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.

The Aroon Indicator entered an Uptrend today. In 198 of 284 cases where ORCL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORCL as a result. In 43 of 68 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.

The Moving Average Convergence Divergence Histogram (MACD) for ORCL turned negative on September 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 26 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.

ORCL moved below its 50-day moving average on September 24, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ORCL crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.

ORCL broke above its upper Bollinger Band on September 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 24 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.502) is normal, around the industry mean (18.522). P/E Ratio (20.784) is within average values for comparable stocks, (158.311). Projected Growth (PEG Ratio) (0.740) is also within normal values, averaging (3.648). Dividend Yield (0.015) settles around the average of (0.004) among similar stocks. P/S Ratio (5.858) is also within normal values, averaging (104.490).

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. ORCL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Microsoft Corp (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL), Palo Alto Networks Inc (NASDAQ:PANW), Crowdstrike Holdings Inc (NASDAQ:CRWD), Twilio (NYSE:TWLO), Block Inc (NYSE:XYZ), NetApp (NASDAQ:NTAP), Okta (NASDAQ:OKTA), Zscaler (NASDAQ:ZS), MongoDB (NASDAQ:MDB).

Industry description

Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.

Market Cap

The average market capitalization across the Computer Communications Industry is 35.56B. The market cap for tickers in the group ranges from 48.8K to 3.78T. MSFT holds the highest valuation in this group at 3.78T. The lowest valued company is WMHI at 48.8K.

High and low price notable news

The average weekly price growth across all stocks in the Computer Communications Industry was 2%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 26%. BIRD experienced the highest price growth at 46%, while VERI experienced the biggest fall at -43%.

Volume

The average weekly volume growth across all stocks in the Computer Communications Industry was -1%. For the same stocks of the Industry, the average monthly volume growth was -27% and the average quarterly volume growth was -28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 70
Price Growth Rating: 57
SMR Rating: 78
Profit Risk Rating: 91
Seasonality Score: 3 (-100 ... +100)
View a ticker or compare two or three
ORCL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of a diversified line of business software products

Industry ComputerCommunications

Industry
Packaged Software
Address
2300 Oracle Way
Phone
+1 737 867-1000
Employees
141000
Web
https://www.oracle.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.